Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? a retrospective study
AUTOR(ES)
Al-Ghazo, Mohammed A., Ghalayini, Ibrahim F., Al-Azab, Rami S., Bani-Hani, Ibrahim, Barham, Alaa, Haddad, Yazan
FONTE
International braz j urol
DATA DE PUBLICAÇÃO
2010-12
RESUMO
PURPOSE: Define a group of patients with newly diagnosed prostate cancer, whose risk of bone metastasis is low enough to omit a bone scan staging study. MATERIALS AND METHODS: From 2003 to 2009, the medical records of patients who were newly diagnosed with prostate cancer were retrospectively reviewed. The data collected included: age, digital rectal examination, serum prostate specific antigen (PSA), Gleason score, clinical T stage, and bone isotope scan. Patients were divided into two groups according to the results of bone isotope scan; positive group and negative group. A univariate and multivariate binary logistic regression was used to analyze the results. RESULTS: Of the 106 patients, 98 had a complete data collection and were entered into the study. The median age of the patients was 70.5 years and patients with a positive bone scan was 74 years, significantly higher than for patients with negative scans (69 years) (p = 0.02). Bone metastasis was detected in 39 cases (39.7%). In all patients with clinical T1-2 stage, a Gleason score of < 8 and PSA = 20 ng/mL, the bone isotope scans were negative. In univariate analysis, PSA (> 20 ng/mL) and Gleason score (> 7) were independently predictive of positive bone scan, while clinical stage was not. CONCLUSION: Staging bone scans can be omitted in patients with a PSA level of = 20 ng/mL, and Gleason score < 8. Our results suggest that by considering the Gleason score and PSA, a larger proportion of patients with prostate cancer could avoid a staging bone scan.
Documentos Relacionados
- Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study
- Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer
- Special emphasis on bone health management in prostate cancer patients: a prospective longitudinal study
- MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes
- MRI should be routine for all patients with localized prostate cancer? | Opinion: No